艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

ADC 艾格里房产

未开盘 10-01 16:00:00 EDT

65.03

-1.78

-2.66%

盘后65.29

+0.26+0.40%

19:46 EDT

最高67.05	最低65.03	成交量238.78万
今开67.05	昨收66.81	日振幅3.02%
总市值80.88亿	流通市值79.45亿	总股本1.24亿
成交额1.56亿	换手率1.95%	流通股本1.22亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"ADC","market":"US","secType":"STK","nameCN":"艾格里房产","latestPrice":65.03,"timestamp":1790884800000,"preClose":66.81,"halted":0,"volume":2387764,"hourTrading":{"tag":"盘后","latestPrice":65.29,"preClose":65.03,"latestTime":"19:46 EDT","volume":40725,"amount":2647997.0888,"timestamp":1790898386799,"change":0.26,"changeRate":0.003998,"amplitude":0.019837},"delay":0,"changeRate":-0.026642718155964692,"floatShares":122178283,"shares":124379300,"eps":1.85165,"marketStatus":"未开盘","change":-1.78,"latestTime":"10-01 16:00:00 EDT","open":67.045,"high":67.045,"low":65.03,"amount":156244497.793304,"amplitude":0.03016,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":1.85165,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1790928000000},"marketStatusCode":0,"adr":0,"adrRate":0,"listingDate":766296000000,"exchange":"NYSE","adjPreClose":66.81,"dividendRate":0.048301,"preHourTrading":{"tag":"盘前","latestPrice":66.81,"preClose":66.81,"latestTime":"09:08 EDT","volume":80413,"amount":5372398.96304,"timestamp":1790860128218,"change":0,"changeRate":0,"amplitude":0.004939},"postHourTrading":{"tag":"盘后","latestPrice":65.29,"preClose":65.03,"latestTime":"19:46 EDT","volume":40725,"amount":2647997.0888,"timestamp":1790898386799,"change":0.26,"changeRate":0.003998,"amplitude":0.019837},"volumeRatio":1.460849,"impliedVol":0.2573,"impliedVolPercentile":0.8486},"requestUrl":"/m/hq/s/ADC","defaultTab":"news","newsList":[{"id":"2669964109","title":"乐普生物(02157.HK)：CMG901(AZD0901)临床研究结果入选LBA并将于主席研讨会上公布 总计4项临床研究结果入选2026年ESMO大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2669964109","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2669964109?lang=zh_cn&edition=full","pubTime":"2026-09-23 16:36","pubTimestamp":1790152598,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4231","LU0266512127.USD","BK4080","ADC","CRC","NETL","LU0456854461.SGD","BK4213"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1198015374","title":"艾格里房产公司——净收益将用于公司运营、债务削减、收购及开发项目","url":"https://stock-news.laohu8.com/highlight/detail?id=1198015374","media":"美股速递","labels":["merge"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/1198015374?lang=zh_cn&edition=full","pubTime":"2026-09-18 04:06","pubTimestamp":1789675570,"startTime":"0","endTime":"0","summary":"艾格里房产公司近日宣布，其预计获得的净收益将主要用于公司日常运营、债务削减、潜在收购以及房地产开发等方向。通过此番资本配置策略，艾格里房产旨在平衡短期财务稳健性与长期战略布局，从而为股东创造持续价值。未来，随着资金逐步到位，艾格里房产的运营灵活性有望得到进一步提升，而债务压力的缓解也将为其后续扩张提供更坚实的财务基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","NETL","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667367005","title":"优赫得一线治疗HER2突变晚期非鳞状NSCLC中位PFS达14.3个月","url":"https://stock-news.laohu8.com/highlight/detail?id=2667367005","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667367005?lang=zh_cn&edition=full","pubTime":"2026-09-16 14:05","pubTimestamp":1789538700,"startTime":"0","endTime":"0","summary":"9月14日，国际肺癌研究协会2026世界肺癌大会正在召开。会上，阿斯利康和第一三共公布了代号为DESTINY-Lung04的III期临床研究结果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609163875988974.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609163875988974.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK4195","BK4080","PFS","NETL","ADC","BK4211","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667466104","title":"CRO板块强势走高！多家CRO上市公司解密业务近况","url":"https://stock-news.laohu8.com/highlight/detail?id=2667466104","media":"微博财经-财道工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667466104?lang=zh_cn&edition=full","pubTime":"2026-09-14 21:08","pubTimestamp":1789391280,"startTime":"0","endTime":"0","summary":"在互动平台与机构调研中，多家具备CRO业务的上市公司近期密集回应市场关切，披露了订单、产能及全球化布局的最新进展。2026 年上半年，公司实现 CRO 销售收入 4,513.95 万元， 较上年同期增长 10.91%。截至 2026 年上半年末，客户群体不断扩大，累计服务超过 16,900 家研发实验室客户。CRO 业务毛利率基本保持相对稳定水平，具体受服务类型、项目内容影响有所波动。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/wbstock/2026-09-14/doc-inirveaq9305051.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","IBBQ","BK1161","NETL","BK1574","ADC","MEDX","BK4080","BK4231","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665062393","title":"一个还没进临床的分子，凭什么卖出12.95亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665062393","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665062393?lang=zh_cn&edition=full","pubTime":"2026-09-07 10:08","pubTimestamp":1788746914,"startTime":"0","endTime":"0","summary":"对一款尚未进入人体临床试验的资产而言，1.1亿美元的首付款属于明显偏高的定价。2023年，和黄医药将已在中国获批上市的呋喹替尼授权给武田制药：总额11.3亿美元，首付款4亿美元。那是\"成熟产品出海\"的典范，一个经过临床验证、获批上市的分子，换取全球市场权益。HMPL-A830尚未启动I期临床，和黄医药卖的是一个\"概念验证前\"的平台资产，而12.95亿美元的总交易额，已经超过了呋喹替尼的11.3亿美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788491648644278418","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK1191","ADC","BK4080","00013","BK1588","BK4231","NETL","KURE","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663046879","title":"礼来上半年营收427.73亿美元，替尔泊肽占比65%近277亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2663046879","media":"经济参考网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663046879?lang=zh_cn&edition=full","pubTime":"2026-08-30 12:16","pubTimestamp":1788063391,"startTime":"0","endTime":"0","summary":"近日，礼来（EliLillyandCompany，NYSE：LLY）公布2026年上半年及第二季度业绩。财报显示，今年上半年，礼来实现总营收427.73亿美元，同比增长49%。其中第二季度营收达229.74亿美元，同比增长48%，超市场预期。基于上半年的强劲增长势头，礼来将2026年全年营收指引从此前的820亿至850亿美元上调至850亿至870亿美元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202608303859354883.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202608303859354883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2097828474.EUR","LU2097828557.USD","LU0326950275.SGD","BK4230","BK4231","LU2242644610.SGD","BK1583","LU1188198961.HKD","LU1969619763.USD","LU2097828631.EUR","CAR","LU2097828714.EUR","LU0502904849.HKD","HK0000165453.HKD","ADC","LU2328871848.SGD","LU0244354667.USD","BK1589","NETL","BK1161","BK4080","01801","LU2097828805.USD","LU0455707207.USD","BK4022","LU2488822045.USD","LU0463099449.HKD","KURE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661230628","title":"基石药业-B(02616.HK)：CS5007(EGFR/HER3双特异性ADC)IND申请获中国NMPA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2661230628","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661230628?lang=zh_cn&edition=full","pubTime":"2026-08-21 06:08","pubTimestamp":1787263715,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["IND","ADC","BK4231","NETL","BK4080"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660407386","title":"灿芯股份发布28nm高性能SAR ADC IP","url":"https://stock-news.laohu8.com/highlight/detail?id=2660407386","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660407386?lang=zh_cn&edition=full","pubTime":"2026-08-20 16:51","pubTimestamp":1787215892,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4135","BK4080","LU1169590202.USD","WOOD","CUT","SAR","BK4585","LU1481600234.SGD","BK4136","NETL","BK4231","BK4588","LU2463526074.USD","ADC","IE00B3T34201.USD","IP","LU1481599808.USD","LU1169589451.USD","LU1487256676.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248062","title":"阿斯利康(AZN.US)/第一三共ADC一线治疗肺癌III期研究成功","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248062","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660248062?lang=zh_cn&edition=full","pubTime":"2026-08-17 20:44","pubTimestamp":1786970699,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月17日，阿斯利康和第一三共联合宣布Enhertu单药一线治疗非小细胞肺癌的III期DESTINY-Lung04研究取得了高水平的积极结果。结果显示，Enhertu组患者的PFS较标准治疗组实现了统计学显著且临床意义显著的改善。值得一提的是，Enhertu是第一个在III期研究中成功证明单药相较标准治疗作为一线治疗方案能够改善NSCLC患者的PFS的ADC药物。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480994.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4134","LU0432979614.USD","BK4231","BK4080","LU2237443549.SGD","III","AZN","LU2089984988.USD","BK4585","LU0708994859.HKD","BK4588","BK4007","ADC","LU2237443895.HKD","LU0889565916.HKD","IE00B3T34201.USD","LU2237443382.USD","LU0109394709.USD","LU2417539215.USD","LU2237443978.SGD","LU2237443622.USD","LU0128525929.USD","AZNH","LU1267930573.SGD","BK4568","LU2468319806.SGD","LU0029864427.USD","NETL","LU2237443465.HKD","LU0310800379.SGD","LU2456880835.USD","LU0289739699.SGD","LU0320765992.SGD","LU1829250122.USD","LU2462157665.USD","LU0058720904.USD","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659147909","title":"博安生物(06955)：BA1302 (CD228 ADC)完成中国Ia期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2659147909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659147909?lang=zh_cn&edition=full","pubTime":"2026-08-14 22:22","pubTimestamp":1786717377,"startTime":"0","endTime":"0","summary":"智通财经APP讯，博安生物 发布公告，公司自主研发的靶向CD228的创新抗体偶联药物BA1302已完成中国I期临床研究单药剂量递增阶段(Ia期)。研究结果显示，BA1302在经多线治疗后疾病仍进展的多种晚期实体瘤患者中展现出良好的抗肿瘤活性，整体安全耐受性良好。据公司所知，BA1302是目前全球唯一处于临床阶段的靶向CD228 ADC。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1480359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","BK4231","BK1161","NETL","BK4080","06955"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659860121","title":"第一三共/阿斯利康(AZN.US)重磅ADC药物“德曲妥珠单抗”又一项新适应症在中国获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2659860121","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659860121?lang=zh_cn&edition=full","pubTime":"2026-08-13 07:21","pubTimestamp":1786576889,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，8月12日，第一三共宣布，其与阿斯利康合作开发的重磅ADC药物“德曲妥珠单抗”一项新适应症获批上市，适应症为联合帕妥珠单抗用于不可切除或转移性HER2阳性成人乳腺癌患者的一线治疗。德曲妥珠单抗(DS-8201，商品名：优赫得®/Enhertu)是一款靶向HER2的ADC药物，由第一三共开发，并与阿斯利康在全球范围内共同开发和商业化。该药由HER2靶向抗体、可裂解四肽连接子和拓扑异构酶I抑制剂DXd(依喜替康衍生物)组成，DAR约为8。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1479235.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2237443622.USD","BK4231","LU2237443382.USD","LU0889565916.HKD","LU2237443895.HKD","LU0432979614.USD","AZNH","LU0320765992.SGD","LU2456880835.USD","NETL","ADC","LU1829250122.USD","IPOS","LU0310800379.SGD","LU2468319806.SGD","BK4568","LU2462157665.USD","LU0289739699.SGD","LU2237443465.HKD","BK4585","LU1267930573.SGD","LU0058720904.USD","BK4588","AZN","LU0109394709.USD","IE00B3T34201.USD","BK4007","LU0708994859.HKD","LU0128525929.USD","LU2089984988.USD","LU2237443549.SGD","LU0029864427.USD","LU2417539215.USD","BK4080","LU2236285917.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658921431","title":"【券商聚焦】招商证券首予映恩生物（09606）强烈推荐评级 指ADC管线差异化优势显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2658921431","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658921431?lang=zh_cn&edition=full","pubTime":"2026-08-12 14:39","pubTimestamp":1786516786,"startTime":"0","endTime":"0","summary":"金吾财讯 | 招商证券发布研报指，映恩生物 凭借四大自主知识产权ADC技术平台，构建了覆盖肿瘤与自免疾病、从1.0到3.0全梯度的差异化管线。DB-1303针对二线及以上HER2阳性乳腺癌的III期研究已达PFS主要终点，中国BLA于2026年4月获NMPA受理；其子宫内膜癌适应症获中美突破性疗法认定，为全球少数覆盖全HER2表达水平的HER2 ADC。首次覆盖，给予“强烈推荐”投资评级。","market":"nz","thumbnail":"https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MjdmY2Y4OTEwODUyNTc5NjI3Mg==.jpg"],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1988027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCE","06099","ADC","09606"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658961671","title":"1300亿明星药企递表港交所，四川首富的MNC梦想再启程，手握全球首款双抗ADC","url":"https://stock-news.laohu8.com/highlight/detail?id=2658961671","media":"独角兽早知道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658961671?lang=zh_cn&edition=full","pubTime":"2026-08-11 09:01","pubTimestamp":1786410060,"startTime":"0","endTime":"0","summary":"与前三轮递表不同，这一次百利天恒的核心产品宜泽康 已于2026年6月及7月分别获批鼻咽癌和食管鳞癌两项适应症，成为全球首款且唯一获批上市的双特异性抗体ADC药物。2025年9月，公司通过港交所聆讯，并于11月7日启动公开招股，原定11月17日挂牌上市。宜泽康是全球迄今首款且唯一获批上市的双特异性抗体ADC药物，同时也是唯一进入全球注册阶段的EGFR×HER3双抗ADC。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MzU3MTY1MzExOQ==&mid=2247612509&idx=1&sn=8b6192e7c76d04a77d55fee0c4fce903&chksm=fdff22475b2583cbf8b6fc2df321005568ea0af5c1c34dce1fbfcc5e1c7e16dcd2c2ac0d6741&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["ADC","BK4231","NETL","BK4080","IPOS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657622723","title":"ADC的矿源耗竭了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657622723","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657622723?lang=zh_cn&edition=full","pubTime":"2026-08-08 11:39","pubTimestamp":1786160396,"startTime":"0","endTime":"0","summary":"于是我们听见，行业里开始流行一句半开玩笑的问话：ADC的矿源耗竭了吗？01 三代挖矿者同挖一座山ADC的矿，指的是可成药抗原：抗体识别细胞表面靶点，偶联毒素定向爆破。但到2026年，矿脉分布已经畸形：HER2：全球临床试验318项，中国企业在该靶点ADC在研数量占全球63.6%，2026年ASCO摘要池里HER2相关48个分子、104项研究，Enhertu一家占了21条。02 开采成本翻了几倍矿源耗竭的体感，来自五重挤压。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1785379137813045498","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["ADC","NETL","BK4080","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657641539","title":"百济神州：公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2657641539","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657641539?lang=zh_cn&edition=full","pubTime":"2026-08-07 21:24","pubTimestamp":1786109040,"startTime":"0","endTime":"0","summary":"百济神州在接受调研时表示，公司拟披露CEA ADC在非小细胞肺癌中的早期数据，覆盖鳞癌和非鳞癌患者。具体的CEA表达阈值、PD-L1表达分层及对应疗效尚未对外披露，后续数据将提供更多信息。公司不会将该产品局限于后线，正在加快向更前线及与PD-1等方案联合推进。对于CEA与KRAS共突变等细分人群，也会根据表达重叠度和早期信号开展探索。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-08-07/doc-inimpfyi4628080.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1251922891.USD","ONC","688235","LU1719994722.HKD","LU1770034418.SGD","BK4080","BK1588","BK4139","LU1303224171.USD","LU2328871848.SGD","LU0588546209.SGD","ADC","LU1969619763.USD","BK4588","BK1583","BK0239","BK4231","LU0307460666.USD","06160","BK1161","BK4526","BK4585","KURE","NETL","BK1500"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657505243","title":"港股异动 | 科伦博泰生物(06990)午前涨超4% 新型双载荷ADC药物SKB565新药临床试验申请获批","url":"https://stock-news.laohu8.com/highlight/detail?id=2657505243","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657505243?lang=zh_cn&edition=full","pubTime":"2026-08-06 11:16","pubTimestamp":1785986197,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，科伦博泰生物(06990)午前涨超4%，截至发稿，涨3.8%，报510.5港元，成交额9592.4万港元。消息面上，科伦博泰生物近日发布公告，公司收到国家药品监督管理局药品审评中心的临床试验通知书，同意其新型双载荷ADC药物SKB565的新药临床试验申请，用于治疗晚期实体瘤。这是公司首个进入临床阶段的“双载荷”抗体偶联药物，SKB565的获批标志着公司在“ADC+IO”一体化开发策略上迈出关键一步。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1476639.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMED","NETL","06990","LU0196878994.USD","PSYK","IBBQ","BK4585","KCAI","VXUS","IBBJ","BK4080","BK1161","ADC","MDTX","BK4231","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656538672","title":"港股异动 | 百奥赛图-B(02315)涨超10% 双抗ADC推进海外开发 临床前CRO与模型鼠景气度上行","url":"https://stock-news.laohu8.com/highlight/detail?id=2656538672","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656538672?lang=zh_cn&edition=full","pubTime":"2026-08-04 15:00","pubTimestamp":1785826839,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B涨超10%，截至发稿，涨10.39%，报57.9港元，成交额8028.46万港元。消息面上，百奥赛图上月宣布与Whitehawk Therapeutics, Inc.签署一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进多元化的新一代治疗产品管线。据悉，从双方正式启动合作到完成协议签署，历时仅仅约四个月。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","NETL","BK4585","02315","BK4080","BK0216","KCAI","BK4588","VXUS","BK1161","ADC","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656963586","title":"康宁杰瑞制药-B早盘涨超12% TROP2/HER3双抗ADC授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656963586","media":"新浪港股","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656963586?lang=zh_cn&edition=full","pubTime":"2026-08-04 09:54","pubTimestamp":1785808440,"startTime":"0","endTime":"0","summary":"模拟交易客户端康宁杰瑞制药-B早盘涨超12%，截至发稿，股价上涨12.43%，现报8.32港元，成交额762.18万港元。康宁杰瑞生物制药宣布，其全资子公司江苏康宁杰瑞生物制药有限公司与Pathos AI， Inc．就康宁杰瑞自主研发的同类首创新药TROP2/HER3双特异性抗体偶联药物JSKN016达成授权许可协议。作为本次授权合作的一部分，康宁杰瑞获得Pathos授予的一份认股权证，有权认购Pathos的优先股股份，认购总价为6，250万美元。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-08-04/doc-inimchzt5433129.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09966","BK1574","BK1161","ADC","BK4080","BK4231","NETL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656248463","title":"中国生物制药(01177)：TQB2102“HER2双抗ADC”第三次被CDE纳入突破性治疗药物名单","url":"https://stock-news.laohu8.com/highlight/detail?id=2656248463","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656248463?lang=zh_cn&edition=full","pubTime":"2026-08-03 16:37","pubTimestamp":1785746238,"startTime":"0","endTime":"0","summary":"智通财经APP讯，中国生物制药 发布公告，集团附属公司正大天晴药业集团股份有限公司自主研发的国家1类创新药TQB2102“HER2双抗 ADC”已被中国国家药品监督管理局药品审评中心纳入突破性治疗药物名单，用于在复发或转移性疾病阶段未接受过化疗的不可切除或转移性HER2低表达成人乳腺癌患者。这是继HER2阳性早期乳腺癌新辅助治疗、HER2 IHC 3+晚期结直肠癌之后，TQB2102获得的第三项突破性疗法认定，进一步印证了其在HER2表达实体瘤治疗领域的广泛应用潜力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475261.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1223082519.USD","BK1515","BK4080","LU1223082196.USD","BK1589","LU1223083913.SGD","CDE","IE00BZ08YR35.GBP","SIL","XME","ADC","BK1191","NETL","IE00BZ08YT58.USD","HK0000165453.HKD","01177","BK4017","GDXJ","IE00BZ08YS42.EUR","BK1521","BK4231","SGDM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656432314","title":"港股异动 | 百奥赛图-B(02315)午后涨超8% 近期与Whitehawk达成合作 旗下5款双抗ADC出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2656432314","media":"智通财经网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656432314?lang=zh_cn&edition=full","pubTime":"2026-08-03 14:28","pubTimestamp":1785738520,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，百奥赛图-B午后涨超8%，截至发稿，涨6.28%，报53.3港元，成交额5248.07万港元。消息面上，近日，百奥赛图与Whitehawk Therapeutics达成一项全球战略合作协议，涵盖多个双特异性抗体偶联药物研发项目，双方将共同推进新一代治疗产品管线。据悉，Whitehawk将对百奥赛图提供的五款双特异性抗体进行评估，并有权选择将任何由此产生的ADC候选药物推进至其研发管线中，百奥赛图将获得一定数额的首付款及潜在里程碑付款。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475186.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["VXUS","BK4588","KCAI","NETL","688796","BK0216","BK4231","02315","BK4585","BK1161","BK4080","ADC"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.agreerealty.com","stockEarnings":[{"period":"1week","weight":-0.0046},{"period":"1month","weight":-0.0753},{"period":"3month","weight":-0.1414},{"period":"6month","weight":-0.1279},{"period":"1year","weight":-0.0595},{"period":"ytd","weight":-0.0725}],"compareEarnings":[{"period":"1week","weight":-0.0067},{"period":"1month","weight":-0.0058},{"period":"3month","weight":0.024},{"period":"6month","weight":0.1628},{"period":"1year","weight":0.1448},{"period":"ytd","weight":0.1184}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"Agree Realty Corporation成立于1971年，是马里兰州的一家公司。该公司是一家完全整合的房地产投资信托基金，主要专注于净出租给行业领先租户的零售物业的所有权、收购、开发和管理。","yearOnYearQuotes":[{"month":1,"riseRate":0.59375,"avgChangeRate":-0.003579},{"month":2,"riseRate":0.46875,"avgChangeRate":0.002186},{"month":3,"riseRate":0.5625,"avgChangeRate":0.012831},{"month":4,"riseRate":0.59375,"avgChangeRate":0.003425},{"month":5,"riseRate":0.484848,"avgChangeRate":0.013996},{"month":6,"riseRate":0.666667,"avgChangeRate":0.010466},{"month":7,"riseRate":0.666667,"avgChangeRate":0.022977},{"month":8,"riseRate":0.454545,"avgChangeRate":-0.000027},{"month":9,"riseRate":0.454545,"avgChangeRate":-0.008411},{"month":10,"riseRate":0.5625,"avgChangeRate":-0.000339},{"month":11,"riseRate":0.65625,"avgChangeRate":0.003584},{"month":12,"riseRate":0.46875,"avgChangeRate":0.00994}],"exchange":"NYSE","name":"艾格里房产","nameEN":"Agree"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.50.1","shortVersion":"4.50.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"艾格里房产,ADC,艾格里房产股票,艾格里房产股票老虎,艾格里房产股票老虎国际,艾格里房产行情,艾格里房产股票行情,艾格里房产股价,艾格里房产股市,艾格里房产股票价格,艾格里房产股票交易,艾格里房产股票购买,艾格里房产股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"艾格里房产(ADC)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供艾格里房产(ADC)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}